Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by BottomBrokeron Sep 25, 2024 3:31pm
228 Views
Post# 36240849

Insider buying

Insider buyingNow I'm no conspiracy theorist, but damned if I'm not wondering if there's some sort of coincidence between the stubbornly low stock price and ...

https://www.tipranks.com/experts/insiders/patrick-d.-kirwin#google_vignette

Patrick D. Kirwin, Director at ProMIS Neurosciences, holds 99.10K shares in ProMIS Neurosciences (Ticker: PMN). Most recently, Patrick D. Kirwin Bought $10,000 shares of ProMIS Neurosciences on Aug 15, 2024 for an estimated value of 12.40K

https://ph.investing.com/news/stock-market-news/promis-neurosciences-director-shafmaster-purchases-255750-in-stock-93CH-1452221

In a recent series of transactions, Madge K. Shafmaster, a director at ProMIS Neurosciences Inc. (OTC:PMN), made significant purchases of company stock, totaling $255,750. These acquisitions were made over three separate days, with prices ranging from $1.2511 to $1.3004 per share.

On September 20, 2024, Shafmaster bought 60,000 shares at $1.2511 each. This was followed by a purchase of 70,000 shares at $1.2808 per share on September 23, and another 70,000 shares at $1.3004 each on September 24. The transactions collectively increased Shafmaster's holdings to 208,333 common shares in the pharmaceutical preparations company.

These stock purchases by a member of ProMIS Neurosciences' board indicate a bolstering of Shafmaster's investment in the company, as reflected by the public filing. For investors, such insider transactions can offer insights into the confidence that company executives and directors have in the firm's future prospects.

<< Previous
Bullboard Posts
Next >>